Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBT (2016 - 2026)

Ironwood Pharmaceuticals' EBT history spans 16 years, with the latest figure at $91.6 million for Q4 2025.

  • On a quarterly basis, EBT rose 164.0% to $91.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $161.2 million, a 258.16% increase, with the full-year FY2025 number at $161.2 million, up 258.16% from a year prior.
  • EBT hit $91.6 million in Q4 2025 for Ironwood Pharmaceuticals, up from $68.0 million in the prior quarter.
  • Over the last five years, EBT for IRWD hit a ceiling of $91.6 million in Q4 2025 and a floor of -$1.1 billion in Q2 2023.
  • Historically, EBT has averaged -$33.1 million across 5 years, with a median of $43.3 million in 2021.
  • Biggest five-year swings in EBT: soared 1106.52% in 2021 and later tumbled 2100.97% in 2023.
  • Tracing IRWD's EBT over 5 years: stood at $46.3 million in 2021, then skyrocketed by 56.23% to $72.3 million in 2022, then plummeted by 371.46% to -$196.2 million in 2023, then rose by 27.06% to -$143.1 million in 2024, then skyrocketed by 164.0% to $91.6 million in 2025.
  • Business Quant data shows EBT for IRWD at $91.6 million in Q4 2025, $68.0 million in Q3 2025, and $37.8 million in Q2 2025.